Shopping Cart 0
Cart Subtotal
AED 0

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) - Pipeline Review, H1 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 7340

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 14680

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 22020

Details

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H1 2018

 

Summary

 

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H1 2018, provides an overview of the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline landscape.

 

Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications.

 

Report Highlights

 

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 4, 6 and 1 respectively.

 

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Scope

 

- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System)

 

Reasons to buy

 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Overview

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Companies Involved in Therapeutics Development

AFFiRiS AG

Corestem Inc

Denali Therapeutics Inc

ICB International Inc

Neuropore Therapies Inc

Prana Biotechnology Ltd

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Drug Profiles

Anle-138b-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System Atrophy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-10BR05-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENT-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-20011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBT-434-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-03-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Neurodegenerative Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UB-312-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Discontinued Products

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Product Development Milestones

Featured News & Press Releases

Mar 06, 2018: PBT434 poster presented at the 6th International Multiple System Atrophy Conference

Mar 01, 2018: AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs PD01A

Mar 01, 2018: AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs PD03A

Dec 04, 2017: ICBII Announces the Filing of Orphan Drug Designation Application for the Use of alpha-Synuclein-SMART Molecule in the Treatment of Multiple System Atrophy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018


List Of Table

List of Tables

Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by AFFiRiS AG, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by Corestem Inc, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by Denali Therapeutics Inc, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by ICB International Inc, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by Neuropore Therapies Inc, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by Prana Biotechnology Ltd, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Discontinued Products, H1 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Therapeutic Products under Development, Key Players in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Therapeutics, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Overview, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Assessment


Companies

AFFiRiS AG

Corestem Inc

Denali Therapeutics Inc

ICB International Inc

Neuropore Therapies Inc

Prana Biotechnology Ltd

Company Profile

Company Profile Title

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H1 2018

 

Summary

 

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H1 2018, provides an overview of the Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline landscape.

 

Multiple system atrophy (MSA) or Shy-Drager syndrome is a neurological disorder that impairs body's involuntary functions (blood pressure, heart rate, bladder function and digestion). Symptoms include rigid muscles, bradykinesia, Tremors, dysarthria, dysphagia, constipation, incontinence and irregular heartbeat. Treatment is aimed at relieving symptoms with anti-Parkinson's medications.

 

Report Highlights

 

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

 

The Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 4, 6 and 1 respectively.

 

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

 

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

 

Scope

 

- The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System)

 

Reasons to buy

 

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Overview

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Companies Involved in Therapeutics Development

AFFiRiS AG

Corestem Inc

Denali Therapeutics Inc

ICB International Inc

Neuropore Therapies Inc

Prana Biotechnology Ltd

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Drug Profiles

Anle-138b-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antibody to Inhibit Alpha Synuclein for Parkinson's Disease and Multiple System Atrophy-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-10BR05-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENT-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit Alpha Synuclein for Central Nervous System Disorders-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NPT-20011-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBT-434-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-01-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-03-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Neurodegenerative Disease-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

UB-312-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Discontinued Products

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Product Development Milestones

Featured News & Press Releases

Mar 06, 2018: PBT434 poster presented at the 6th International Multiple System Atrophy Conference

Mar 01, 2018: AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs PD01A

Mar 01, 2018: AFFiRiS Announces Results of a Phase I Clinical Study Using AFFITOPEs PD03A

Dec 04, 2017: ICBII Announces the Filing of Orphan Drug Designation Application for the Use of alpha-Synuclein-SMART Molecule in the Treatment of Multiple System Atrophy

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018


List Of Table

List of Tables

Number of Products under Development for Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration), H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by AFFiRiS AG, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by Corestem Inc, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by Denali Therapeutics Inc, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by ICB International Inc, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by Neuropore Therapies Inc, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Pipeline by Prana Biotechnology Ltd, H1 2018

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)-Discontinued Products, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Therapeutic Products under Development, Key Players in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Therapeutics, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Overview, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline, Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) Pipeline Assessment


Companies

AFFiRiS AG

Corestem Inc

Denali Therapeutics Inc

ICB International Inc

Neuropore Therapies Inc

Prana Biotechnology Ltd